<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35907106</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-8218</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neuroscience bulletin</Title><ISOAbbreviation>Neurosci Bull</ISOAbbreviation></Journal><ArticleTitle>UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs.</ArticleTitle><Pagination><StartPage>1431</StartPage><EndPage>1434</EndPage><MedlinePgn>1431-1434</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12264-022-00924-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xi</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-0248-8161</Identifier><AffiliationInfo><Affiliation>Department of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Heling</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gerontology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. chuheling85@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6630-112X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China. drdongyi@yeah.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Neurosci Bull</MedlineTA><NlmUniqueID>101256850</NlmUniqueID><ISSNLinking>1995-8218</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35907106</ArticleId><ArticleId IdType="pmc">PMC9672290</ArticleId><ArticleId IdType="doi">10.1007/s12264-022-00924-8</ArticleId><ArticleId IdType="pii">10.1007/s12264-022-00924-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wen X, An P, Li H, Zhou Z, Sun Y, Wang J, et al. Tau accumulation via reduced autophagy mediates GGGGCC repeat expansion-induced neurodegeneration in Drosophila model of ALS. Neurosci Bull. 2020;36:1414&#x2013;1428. doi: 10.1007/s12264-020-00518-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-020-00518-2</ArticleId><ArticleId IdType="pmc">PMC7719145</ArticleId><ArticleId IdType="pubmed">32500377</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CGJ, Blauw HM, van Vught PWJ, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;1087. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: A population-based study. Neurobiol Aging. 2013;34:357.e1&#x2013;357.e5. doi: 10.1016/j.neurobiolaging.2012.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.016</ArticleId><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Quade B, Camacho M, Zhao X, Orlando M, Trimbuch T, Xu J, et al. Membrane bridging by Munc13-1 is crucial for neurotransmitter release. eLife. 2019;8:e42806. doi: 10.7554/eLife.42806.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.42806</ArticleId><ArticleId IdType="pmc">PMC6407922</ArticleId><ArticleId IdType="pubmed">30816091</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hme MA, Beis C, Reddy-Alla S, Reynolds E, Mampell MM, Grasskamp AT, et al. Active zone scaffolds differentially accumulate Unc13 isoforms to tune Ca2+ channel&#x2013;vesicle coupling. Nat Neurosci. 2016;19:1311&#x2013;1320. doi: 10.1038/nn.4364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4364</ArticleId><ArticleId IdType="pubmed">27526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoqueaux F, Sons MS, Plomp JJ, Brose N. Aberrant morphology and residual transmitter release at the Munc13-deficient mouse neuromuscular synapse. Mol Cell Biol. 2005;25:5973&#x2013;5984. doi: 10.1128/MCB.25.14.5973-5984.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.14.5973-5984.2005</ArticleId><ArticleId IdType="pmc">PMC1168806</ArticleId><ArticleId IdType="pubmed">15988013</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;ri&#xe8;pe J, Fossouo L, Parker JA. Neurodegeneration in C. elegans models of ALS requires TIR-1/Sarm1 immune pathway activation in neurons. Nat Commun. 2015;6:7319. doi: 10.1038/ncomms8319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8319</ArticleId><ArticleId IdType="pubmed">26059317</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo M. Antisense oligonucleotide-mediated exon-skipping therapies: Precision medicine spreading from Duchenne muscular dystrophy. JMA J. 2021;4:232&#x2013;240. doi: 10.31662/jmaj.2021-0019.</Citation><ArticleIdList><ArticleId IdType="doi">10.31662/jmaj.2021-0019</ArticleId><ArticleId IdType="pmc">PMC8355726</ArticleId><ArticleId IdType="pubmed">34414317</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673&#x2013;694. doi: 10.1038/s41573-020-0075-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0075-7</ArticleId><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi E, Koo T. CRISPR technologies for the treatment of Duchenne muscular dystrophy. Mol Ther. 2021;29:3179&#x2013;3191. doi: 10.1016/j.ymthe.2021.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.002</ArticleId><ArticleId IdType="pmc">PMC8571109</ArticleId><ArticleId IdType="pubmed">33823301</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489&#x2013;1498. doi: 10.1016/S0140-6736(17)31611-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31611-2</ArticleId><ArticleId IdType="pubmed">28728956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: Gains, losses, and implications for future therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Chen CY, Wu MC, Wang YC, Tseng YH, et al. Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol Commun. 2019;7:50. doi: 10.1186/s40478-019-0674-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0674-x</ArticleId><ArticleId IdType="pmc">PMC6440020</ArticleId><ArticleId IdType="pubmed">30922385</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Qiao T, Yu J, Wang H, Guo Y, Salameh J, et al. Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice. PLoS One. 2022;17:e0255710. doi: 10.1371/journal.pone.0255710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255710</ArticleId><ArticleId IdType="pmc">PMC8812852</ArticleId><ArticleId IdType="pubmed">35113871</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Ouyang Z, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel FC, Weber SS, Supper J, Zell A, Kahle PJ. TDP-43 regulates global translational yield by splicing of exon junction complex component SKAR. Nucleic Acids Res. 2012;40:2668&#x2013;2682. doi: 10.1093/nar/gkr1082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr1082</ArticleId><ArticleId IdType="pmc">PMC3315294</ArticleId><ArticleId IdType="pubmed">22121224</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS One. 2012;7:e43120. doi: 10.1371/journal.pone.0043120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043120</ArticleId><ArticleId IdType="pmc">PMC3416794</ArticleId><ArticleId IdType="pubmed">22900096</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>